CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL
✉ Email this page to a colleague
All Clinical Trials for CANDESARTAN CILEXETIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00108706 ↗ | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | Takeda | Phase 4 | 2004-12-01 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00108706 ↗ | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | City Hospitals Sunderland NHS Foundation Trust | Phase 4 | 2004-12-01 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00120003 ↗ | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Completed | AstraZeneca | Phase 3 | 2005-06-01 | The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo |
| NCT00120003 ↗ | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Completed | Southern-Eastern Norway Health Authorities RHF | Phase 3 | 2005-06-01 | The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo |
| NCT00120003 ↗ | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Completed | Takeda | Phase 3 | 2005-06-01 | The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo |
| NCT00120003 ↗ | Scandinavian Candesartan Acute Stroke Trial (SCAST) | Completed | Ullevaal University Hospital | Phase 3 | 2005-06-01 | The purpose of this trial is to assess whether the blood pressure lowering agent candesartan (an angiotensin receptor type 1 blocker) is effective when given to patients with acute stroke and elevated blood pressure. Hypothesis: AT1 receptor blockade with candesartan in acute stroke will: 1. reduce the risk of death or major disability at 6 months by a 6% absolute risk reduction, relative to placebo. 2. reduce the risk of the combined event of "vascular" death, myocardial infarction, or stroke during the first 6 months by a 25% relative risk reduction, relative to placebo |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CANDESARTAN CILEXETIL
Condition Name
Clinical Trial Locations for CANDESARTAN CILEXETIL
Trials by Country
Clinical Trial Progress for CANDESARTAN CILEXETIL
Clinical Trial Phase
Clinical Trial Sponsors for CANDESARTAN CILEXETIL
Sponsor Name
